Letters to the Editor

Combination therapy of a PSEN1-selective γ-secretase inhibitor with dexamethasone and an XPO1 inhibitor to target T-cell acute lymphoblastic leukemia

Center for Human Genetics, KU Leuven, Leuven, Belgium; Center for Cancer biology, VIB, Leuven, Belgium; Leuvens Kanker Instituut (LKI), KU Leuven – UZ Leuven, Leuven
Center for Human Genetics, KU Leuven, Leuven, Belgium; Center for Cancer biology, VIB, Leuven, Belgium; Leuvens Kanker Instituut (LKI), KU Leuven – UZ Leuven, Leuven
Center for Human Genetics, KU Leuven, Leuven, Belgium; Center for Cancer biology, VIB, Leuven, Belgium; Leuvens Kanker Instituut (LKI), KU Leuven – UZ Leuven, Leuven
Center for Human Genetics, KU Leuven, Leuven, Belgium; Center for Cancer biology, VIB, Leuven, Belgium; Leuvens Kanker Instituut (LKI), KU Leuven – UZ Leuven, Leuven
Center for Cancer biology, VIB, Leuven
Leuvens Kanker Instituut (LKI), KU Leuven – UZ Leuven, Leuven, Belgium; Department of Hematology, UZ Leuven, Leuven, Belgium; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven
Leuvens Kanker Instituut (LKI), KU Leuven – UZ Leuven, Leuven, Belgium; Department of Oncology, KU Leuven, Leuven, Belgium; Department of Pediatric Oncology, UZ Leuven, Leuven
Center for Human Genetics, KU Leuven, Leuven, Belgium; Center for Cancer biology, VIB, Leuven, Belgium; Leuvens Kanker Instituut (LKI), KU Leuven – UZ Leuven, Leuven
Vol. 108 No. 9 (2023): September, 2023 https://doi.org/10.3324/haematol.2022.282144